Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock
- 1 October 1996
- journal article
- laboratory investigation
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 24 (10) , 1724-1728
- https://doi.org/10.1097/00003246-199610000-00021
Abstract
Objective Lisofylline is an enantiomer-specific, alkyl-substituted methylxanthine, which has specific and potent activity in down-regulating leukocyte activation. This study was designed to test the efficacy of lisofylline in the resuscitation of rats subjected to experimental hemorrhagic shock. Design Prospective, randomized, and blinded survival studies were performed with two lisofylline dosing regimens added to fluid resuscitation in a shock model. In addition, white cell adhesiveness was measured to assess the effects of lisofylline. Setting Animal laboratory. Subjects Sixty Sprague-Dawley rats. Interventions Lisofylline or placebo was added to the resuscitation regimen, either as a single dose or over 24 hrs. Measurements and Main Results The 72-hr survival rate, white blood cell count, and platelet adhesiveness were determined. When a single, 1-hr infusion of lisofylline was added to the initial resuscitation regimen, the 72-hr survival rate increased from 20% in controls to 50% (p < .009). When repeated doses of lisofylline were given over 24 hrs, the 72-hr survival rate increased from 40% in controls to 70% (p < .02). Control animals significantly increased leukocyte adhesiveness after shock and resuscitation. This increased adhesiveness was completely eliminated by lisofylline infusion. Platelet adhesiveness was not affected by lisofylline. Conclusions Lisofylline improves survival in this model of hemorrhagic shock. Its beneficial effect may be related to down-regulation of leukocyte adhesiveness. (Crit Care Med 1996; 24:1724-1728)Keywords
This publication has 9 references indexed in Scilit:
- Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice.The Journal of Experimental Medicine, 1995
- Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid.Proceedings of the National Academy of Sciences, 1994
- CT-1501R SELECTIVELY INHIBITS INDUCED INFLAMMATORY MONOKINES IN HUMAN WHOLE BLOOD EX VIVOShock, 1994
- Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenesNature, 1993
- Immunologic alterations in a murine model of hemorrhagic shockCritical Care Medicine, 1992
- Pentoxifylline in resuscitation of experimental hemorrhagic shockCritical Care Medicine, 1991
- Tumor necrosis factor alpha priming of phospholipase D in human neutrophilsPublished by Elsevier ,1991
- Granulocytes and no-reflow phenomenon in irreversible hemorrhagic shock.Circulation Research, 1988
- A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits.Journal of Clinical Investigation, 1988